Journal
ANNALS OF NEUROLOGY
Volume 84, Issue 1, Pages 110-116Publisher
WILEY
DOI: 10.1002/ana.25273
Keywords
-
Categories
Funding
- ALS Foundation Netherlands
- Belgian ALS Liga and National Lottery
- Agency for Innovation by Science and Technology
- Motor Neuron Disease Association (UK)
- European Community
- ZonMW
- JPND
- UK, Medical Research Council
- UK, Economic and Social Research Council
- Ireland, Health Research Board
- Netherlands, ZonMw
- Belgium, FWO-Vlaanderen
- Motor Neurone Disease Association
- Wellcome Trust
- Netherlands Organization for Health Research and Development
- MRC [MR/R024804/1] Funding Source: UKRI
Ask authors/readers for more resources
ObjectiveAfter the initial report of a CHCHD10 mutation in mitochondrial disease with features resembling amyotrophic lateral sclerosis (ALS), CHCHD10 mutations have been considered to be a frequent cause for ALS. However, the exact pathogenicity and clinical significance of these mutations remain unclear. Here, we aimed to determine the role of CHCHD10 mutations in ALS. MethodsWe analyzed 4,365 whole genome sequenced ALS patients and 1,832 controls from 7 different countries and examined all nonsynonymous single nucleotide variants in CHCHD10. These were tested for association with ALS, independently and in aggregate using several genetic burden tests (including sequence kernel association test [SKAT], optimal unified test [SKAT-O], and Firth logistic regression). ResultsWe identified 3 new variants in cases, but only 1 was ALS-specific. Also, 1 control-specific mutation was identified. There was no increased burden of rare coding mutations among ALS patients compared to controls (p=0.86, p=0.86, and p=0.88 for SKAT, SKAT-O, and Firth, respectively). The few carriers with potential pathogenic CHCHD10 mutations exhibited a slowly progressive ALS-like phenotype with atypical features such as myopathy and deafness. InterpretationCHCHD10 mutations seem to be a far less prevalent cause of pure ALS than previously suggested, and instead appear related to more complex phenotypes. There appears to be insufficient evidence for the pathogenicity of most previously reported variants in pure ALS. This study shows that routine testing for CHCHD10 mutations in pure ALS is not recommended and illustrates the importance of sufficient genetic and functional evidence in establishing pathogenicity of genetic variants. Ann Neurol 2018;83:110-116
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available